Patients HCPs
This site is for US health care professionals only.
A picture of Payne, an infant with SMA, smiling and holding a gold club, framed inside a 3D object in the shape of the number 1x

The one-time-only dose to stop SMA progression

ZOLGENSMA is a gene replacement therapy for pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) that is delivered as a single-dose, 1-hour infusion. Baseline tests and post-infusion monitoring for at least 3 months after infusion are required. Administration of a systemic corticosteroid before and after infusion is also required.1

SEE EFFICACY DATA
Brady, an infant with SMA, sitting on his mother Nicole's lap

Novartis Patient SupportTM and provider support

"It was amazing to have [Novartis Patient Support] reach out so quickly because we felt like we had someone in our corner."
— Nicole, Brady’s mom

ACCESS PATIENT SUPPORT
References: 1. ZOLGENSMA. Prescribing information. Novartis Gene Therapies, Inc. 2. Glascock J, Sampson J, Haidet-Phillips A, et al. Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening. J Neuromuscul Dis. 2018;5(2):145-158.